💊
Arzerra
ofatumumab
Kronisk B-cellslymfatisk leukemi
🚫 Dragen tillbaka
✅
Inga aktiva aviseringar
Denna medicin har inga pågående brister, säkerhetsbrev eller återkallelser.
Vad det används till
Previously untreated chronic lymphocytic leukaemia (CLL): Arzerra in combination with chlorambucil or bendamustine is indicated for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy. Relapsed CLL: Arzerra is indicated in combination with fludarabine and cyclophosphamide for the treatment of adult patients with relapsed CLL. Refractory CLL: Arzerra is indicated for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.
⚠️ Patientsäkerhet
No
Officiell EMA-sida
https://www.ema.europa.eu/en/medicines/human/EPAR/arzerra